F. Hoffmann-La Roche AG

Switzerland

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com/.

Roche retains sole responsibility for content © 2016 F. Hoffmann-La Roche Ltd. All trademarks used or mentioned in this release are protected by law.

1 September 2015 - 31 August 2016

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 September 2015 - 31 August 2016 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC FC WFC
158 55.69 55.69

Outputs by subject (WFC)

Subject AC FC WFC
Life Sciences 123 42.01 42.01
Chemistry 43 16.25 16.25

Highlight of the month: F. Hoffmann-La Roche AG

Antibiotic – antibody combination puts drug-resistant staph in its crosshairs

© Callista Images / Cultura / Getty

© Callista Images / Cultura / Getty

A new antibiotic-antibody combination drug has been developed by researchers, including some from Genentech (a member of the Roche group), that targets and kills stubborn ‘superbug’ bacteria. These resilient bugs, such as methicillin-resistant S. aureus, better-known as MRSA, are resistant to traditional antibiotics and can cause serious infections such as sepsis once they make it into the bloodstream.

The US-Danish team joined an anti-S.aureus antibody to an antibiotic and tested its effectiveness in both in vitro and in vivo environments. The beauty of their approach was that the antibody only targeted ‘host cells’ that had been invaded by the bacteria, which enabled delivery of the drug right where it needed to be. This targeting will allow the effective use of smaller amounts of antibiotics, “it’s another way to repurpose some previously shelved antibiotics.” Sanjeev Mariathasan from Genentech told The Guardian.

  1. Nature 2015; 527, 323. doi: 10.1038/nature16057

View the article on the Nature Index

1 September 2015 - 31 August 2016

International vs. domestic collaboration by WFC

  • 6.01% Domestic
  • 93.99% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs